HLA-A and triple-negative breast carcinoma: In BM, particularly in the basal-like/triple-negative breast cancer (BLBC/TNBC) subtype, human leukocyte antigen-A (HLA-A) DNA methylation or focal deletion hinders the activation of the CD8 + T cell immune response during the recognition stage [74].